BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7672703)

  • 1. Absence of significant germ line p53 mutations in ovarian cancer patients.
    Buller RE; Skilling JS; Kaliszewski S; Niemann T; Anderson B
    Gynecol Oncol; 1995 Sep; 58(3):368-74. PubMed ID: 7672703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
    Lehman TA; Haffty BG; Carbone CJ; Bishop LR; Gumbs AA; Krishnan S; Shields PG; Modali R; Turner BC
    Cancer Res; 2000 Feb; 60(4):1062-9. PubMed ID: 10706125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
    Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
    Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Germline mutation of BRCA1 gene in Polish families with strong aggregation of breast and/or ovarian cancer based on coding sequence analysis using the SSCP method].
    Byrski T
    Ann Acad Med Stetin; 2003; 49():27-43. PubMed ID: 15552838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors.
    Skilling JS; Powills K; Lager DJ; Anderson B; Sorosky J; Buller RE
    Gynecol Oncol; 1996 May; 61(2):180-8. PubMed ID: 8626130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 germline mutations in Indian familial breast cancer.
    Valarmathi MT; A A; Deo SS; Shukla NK; Das SN
    Hum Mutat; 2003 Jan; 21(1):98-9. PubMed ID: 12497638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ-line splicing mutation of the p53 gene in a cancer-prone family.
    Warneford SG; Witton LJ; Townsend ML; Rowe PB; Reddel RR; Dalla-Pozza L; Symonds G
    Cell Growth Differ; 1992 Nov; 3(11):839-46. PubMed ID: 1467311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.
    Zelada-Hedman M; Wasteson Arver B; Claro A; Chen J; Werelius B; Kok H; Sandelin K; Håkansson S; Andersen TI; Borg A; Børresen Dale AL; Lindblom A
    Cancer Res; 1997 Jun; 57(12):2474-7. PubMed ID: 9192828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies.
    Avigad S; Barel D; Blau O; Malka A; Zoldan M; Mor C; Fogel M; Cohen IJ; Stark B; Goshen Y; Stein J; Zaizov R
    Oncogene; 1997 Apr; 14(13):1541-5. PubMed ID: 9129144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population.
    Yamada H; Shinmura K; Okudela K; Goto M; Suzuki M; Kuriki K; Tsuneyoshi T; Sugimura H
    Carcinogenesis; 2007 Sep; 28(9):2013-8. PubMed ID: 17690113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An abundance of p53 null mutations in ovarian carcinoma.
    Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
    Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 expression, mutation, and allelic deletion in ovarian cancer.
    McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
    J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis.
    Güran S; Ozet A; Dede M; Gille JJ; Yenen MC
    Cancer Genet Cytogenet; 2005 Jul; 160(2):164-8. PubMed ID: 15993273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 mutations in familial ovarian cancer.
    Lallas TA; Buekers TE; Buller RE
    Mol Genet Metab; 1999 Aug; 67(4):357-63. PubMed ID: 10444347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A germ line mutation in exon 5 of the p53 gene in an extended cancer family.
    Law JC; Strong LC; Chidambaram A; Ferrell RE
    Cancer Res; 1991 Dec; 51(23 Pt 1):6385-7. PubMed ID: 1933902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France].
    Peyrat JP; Vennin P; Hornez L; Bonneterre J
    Bull Cancer; 1997 Jan; 84(1):41-6. PubMed ID: 9180858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.